Wellness and performance
Digestive & weight
KPV
Also called lysine-proline-valine (α-MSH 11-13)
KPV is a three-amino-acid alpha-MSH fragment studied for inflammation. Evidence is animal and cell-based, with no human efficacy trials. It is not FDA-approved.
- Reviewed by
- William Maish, MD MBA MPH, Clinical Product Lead
- Published
- October 5, 2026
- Last updated
- October 5, 2026
Key takeaway
KPV is a small anti-inflammatory peptide derived from the tail of the hormone alpha-MSH, sold on the "research peptide" market for gut and skin inflammation. Its evidence is preclinical, with no human efficacy trials, though a 2026 FDA advisory committee gave a non-binding favorable vote toward allowing it to be compounded. As of 2026 it is not FDA-approved.
At a glance
| FDA status | Non-FDA-approved peptide sold in the wellness/gray market |
| What it is | Three-amino acid fragment of alpha-MSH with anti-inflammatory activity in lab models |
| Research | Evidence is animal and cell-based only; there are no human efficacy trials |
| Compounding status | A 2026 FDA advisory vote was favorable but non-binding; not yet compoundable on that basis |
| Evidence strength | Low research |
What is KPV?
KPV is a tripeptide (lysine-proline-valine) corresponding to the tail end of alpha-MSH, a hormone with anti-inflammatory properties. It is sold through wellness and "research peptide" channels for gut inflammation, inflammatory bowel conditions, and skin, and it is not an approved medicine.
How does it work?
KPV retains much of alpha-MSH's anti-inflammatory activity. In laboratory models it is taken up into gut and immune cells, where it is proposed to reduce pro-inflammatory signaling, including the NF-kB pathway and downstream inflammatory messengers such as TNF-alpha. Notably, some of its anti-inflammatory activity appears independent of the MC1R receptor. These are cell and animal findings. This describes the proposed mechanism, separate from demonstrated benefit in people.
Is it FDA-approved?
No. KPV is not approved by the FDA. In July 2026 the FDA's Pharmacy Compounding Advisory Committee gave KPV a non-binding favorable vote toward the 503A compounding list. Because that vote is only a recommendation and the FDA has not completed rulemaking, KPV is not currently on the list and cannot be legally compounded on that basis.
What does the research show?
The evidence is preclinical. According to PubMed, two mouse studies of colitis reported these results:
| Form tested | Model | Finding |
| KPV | Mouse models of colitis | Reduced inflammation, partly independent of MC1R (here1) |
| Nanoparticle-delivered KPV | Mice with colitis | Eased colitis, with mucosal healing and reduced TNF-alpha (here2) |
Its anti-inflammatory basis is reviewed here3. There are no controlled human trials establishing KPV for gut or skin use, so its marketed benefit is unproven in people.
More for digestive & weight
Sources: mouse colitis studies of KPV (Kannengiesser et al., Inflammatory Bowel Diseases, 2008, DOI: 10.1002/ibd.203341; Xiao et al., Molecular Therapy, 2017, DOI: 10.1016/j.ymthe.2016.11.0202) and a review of alpha-MSH peptides (Luger and Brzoska, Annals of the Rheumatic Diseases, 2007, DOI: 10.1136/ard.2007.0797803), all indexed on PubMed; and reporting on the July 2026 FDA advisory committee vote. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.